UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K



                                 CURRENT REPORT


                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934


         Date of Report (Date of earliest event reported): June 10, 2003


                         Shire Pharmaceuticals Group plc
- --------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)


                                England and Wales
- --------------------------------------------------------------------------------
                 (State or other jurisdiction of incorporation)


              0-29630                                  98-0359573
     (Commission File Number)              (IRS Employer Identification No.)

Hampshire International Business Park, Chineham, Basingstoke,
Hampshire RG24 8EP England
- --------------------------------------------------------------------------------
(Address of principal executive offices)                        (Zip code)

Registrant's telephone number, including area code        44 1256 894 000



- --------------------------------------------------------------------------------
          (Former name or former address, if changed since last report)






Item 5. Other Events

     Shire Pharmaceuticals Group plc has issued the press releases attached as
Exhibit 99.1, 99.2, and 99.3 and incorporated by reference herein.

Item 7. Financial Statements and Exhibits

     (c) Exhibits. The following exhibits are filed herewith:

99.1     Press Release dated June 10, 2003 relating to share repurchase

99.2     Press Release dated June 10, 2003 relating to application for
         share listing

99.3     Press Release dated June 10, 2003 relating to exercise of stock options








                                    SIGNATURE


     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Dated: June 10, 2003         SHIRE PHARMACEUTICALS GROUP PLC



                             By: /s/ Angus Charles Russell
                                 -----------------------------------
                                 Name:  Angus Charles Russell
                                 Title:  Group Finance Director








                                  EXHIBIT INDEX


Number   Description
- ------   -----------

99.1     Press Release dated June 10, 2003 relating to share repurchase

99.2     Press Release dated June 10, 2003 relating to application for share
         listing

99.3     Press Release dated June 10, 2003 relating to exercise of stock options